为您找到相关结果约500个

你是不是要搜索 期刊左侧RAS/RAF野生型(WT) 转移性结直肠癌（mCRC） 点击跳转

Phase II trial of trametinib (T) and panitumumab (Pmab) in RAS/RAF wild type (wt) metastatic colorectalcancer (mCRC)

A phase Ib/II study of cetuximab and pembrolizumab in RAS-wt mCRC.

Molecular imaging of glutamine (Gln) metabolism in RAS wildtype (WT) metastatic colorectal cancer (mCRC

RAF inhibitors promote RAS-RAF interaction by allosterically disrupting RAF autoinhibition

Is aflibercept an optimal treatment for wt RAS mCRC patients after progression to first line containing

CB-839, panitumumab, and irinotecan in RAS wildtype (WT) metastatic colorectal cancer (mCRC): Phase I

Dihydrosanguinarine suppresses pancreatic cancer cells via regulation of mut-p53/WT-p53 and the Ras/Raf

Protomer selectivity of type II RAF inhibitors within the RAS/RAF complex

Plasma ctDNA RAS/RAF mutations analysis for monitoring overall survival (OS) and heterogeneity in metastaticcolorectal cancer patients (mCRC).

Does Ras Activate Raf and PI3K Allosterically?

III study with FOLFIRI plus cetuximab versus FOLFIRI plus cetuximab followed by cetuximab alone in RASand BRAF WT mCRC

Dissecting primary resistance to anti-EGFRs in RAS and BRAF wt metastatic colorectal cancer (mCRC): A

Dissecting primary resistance to anti-EGFRs in RAS and BRAF wt metastatic colorectal cancer (mCRC): A

Dissecting primary resistance to anti-EGFRs in RAS and BRAS wt metastatic colorectal cancer (mCRC): A

RAS Registry: Molecular pathological analysis of RAS mutations in mCRC

为您找到相关结果约500个

共500条页码: 1/34页15条/页